|Articles|June 23, 2023

Short Film Looks to Build Awareness Around Meningitis B Vaccination

The film is part of a GSK campaign, Ask2BSure, that addresses this issue.

Although relatively rare, meningitis B (meningococcal disease), can be especially severe in the young patients it afflicts. It can cause life-threatening complications or even death. Teenagers and young adults aged 16-23 years, are at an increased risk for contracting meningitis because it can spread through common behaviors such as living in close quarters, coughing, sneezing, kissing, and sharing drinks or utensils.

The CDC points out that the meningococcal B vaccine can help protect against meningococcal disease caused by serogroup B. A different meningococcal vaccine is available that can help protect against serogroups A, C, W, and Y.

GSK’s Ask2BSure campaign, which is designed to create awareness for families about vaccination around meningitis B.


As part of their campaign, a short film titled, I Never Thought to Ask: A Mom's Quest for Answers with Soleil Moon Frye” has been developed. It features the actress, documentarian, and GSK spokesperson Soleil Moon Frye, alongside an appearance with actress, Melissa Joan Hart. The film includes interviews with a medical expert, a meningitis survivor and mothers who have lost their children to meningitis B. Frye hears from those impacted by the disease and shares their stories to encourage parents to ask questions and talk with their teen’s provider about meningitis B vaccination.

“I am grateful to the women who shared their personal stories as part of this short film,” said Moon Frye. “They echo my hope that its message encourages parents to talk openly with their teens and their teen’s doctor about the potential serious dangers associated with meningitis B,and most importantly, to advocate for their children.”

For families who have children of age, it is important to know vaccine status. “Asking questions is key–and we hope the film leads to more parents talking to their child’s doctor about meningitis B vaccination,” said Leonard Friedland, MD, vice president and director of Scientific Affairs and Public Health, GSK.

According to the CDC, the recommended ages for the meningitis B (Men B) vaccine is between 16-18 years. The federal agency, “recommends that certain adolescents and young adults should receive a MenB vaccine. They include those at increased risk because of a serogroup B meningococcal disease outbreak and people with certain medical conditions.”

For those interested in viewing the film, they can do so here.


Related to this article

Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
FAQ: Ebola Prevention, Treatment and the Chances of a US Outbreak
As the Bundibugyo virus outbreak in the Democratic Republic of the Congo surpasses 9300 confirmed cases and 4400 deaths, this FAQ explains how the virus spreads, how it presents, why it is hard to diagnose and treat, which vaccines and therapies are being tested, and why CDC considers the risk to the United States low.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.